CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 82 enrolled
Drug / intervention
High Dose Fluzone® (intramuscular) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03022396
NCT03022396Phase 4Completed
CompareCT.gov

Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 2, 2010

Stanford University·interventional·Posted Jan 16, 2017·Updated Aug 21, 2017

In Brief

A Phase 4 clinical trial evaluating High Dose Fluzone® (intramuscular) and Fluzone® (intramuscular) for Influenza. Completed, enrolled 82 participants.

Detailed Summary

This study will investigate response to influenza vaccines in monozygotic and dizygotic twins of different ages.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2017
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.5 years ago

Interventions

High Dose Fluzone® (intramuscular)biological

Licensed seasonal High dose trivalent inactivated influenza

Fluzone® (intramuscular)biological

Licensed seasonal trivalent inactivated influenza